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Abstract: 
Inflammation is a natural biological response that occurs when vascular tissues are subjected to 
harmful stimuli. This process may be beneficial to the host during wound healing and infections 
but can be detrimental if left unchecked. Oxidative stress, the generation of reactive oxygen 
species, is thought to be one component of this response. Fullerenes can counteract reactive 
oxygen species due to their potent antioxidant capabilities. Thus, we hypothesized that these 
molecules may inhibit inflammation. To test this hypothesis we used an in vivo model of phorbol 
12-myristate 13-acetate (PMA)-induced inflammation and examined the effects fullerenes have 
on mitigating this response. We show that PMA-induced inflammation and oedema is 
dramatically inhibited when fullerenes are given prior to challenge. Thus, fullerene derivatives 
may be a novel way to blunt certain inflammatory conditions and facilitate faster recovery of 
damaged tissue. 
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Background 
The inflammatory process is essential for survival, playing an important role in both health and 
disease. However, if left unchecked this inflammatory processes may contribute to a wide variety 
of human disease processes including the more traditionally defined chronic inflammatory 
diseases, such as allergy, arthritis and inflammatory bowel disease as well as systemic 
cardiovascular diseases (atherosclerosis) and blood vessel disorders (circulatory shock). The 
mechanisms leading from the initial injury involves an intricate series of events including 
oedema, oxidative stress, immune cell recruitment, proliferation, migration and differentiation. 
Inappropriate inflammation is usually treated with certain steroids such as glucocorticoids or 
with non-steroidal anti-inflammatory drugs. Both classes of compounds can have undesirable 
side effects (1,2). Discovering new ways to treat inflammation is of clinical importance. 
 
Questions addressed 
Fullerenes have unique biological capabilities and are being investigated as possible therapies for 
a wide range of diseases (3–7). We recently demonstrated that derivatized fullerenes can inhibit 
allergic inflammation in vitro and in vivo in part through the reduction in reactive oxygen species 
(ROS) (8). These studies strongly suggest that fullerenes are capable of targeting mitochondria, 
as others have shown in various cell lines (9–12), where they can affect cellular functions. 
However, the lack of suitable pharmacological formulations of fullerenes has largely prevented 
their development into therapies. Given their wide ranging potential as a new therapeutic 
platform we hypothesized that derivatized fullerene compounds could inhibit the inflammatory 
cascade associated with phorbol 12-myristate 13-acetate (PMA)-induced inflammation. A well-
established mouse model of inflammation was used to show that fullerenes can significantly 
reduce the inflammatory events that lead to cutaneous inflammation. 
Experimental design 
All mice (8-week-old males) were purchased from Charles River Labs, Wilmington, MA, USA 
and humanely treated under standard conditions and with IRB approval. Fullerene derivatives 
were synthesized by adding various molecular entities to the carbon cage. A representative 
fullerene used herein is shown in Fig. 1. Each derivative was purified and characterized using 
matrix-assisted laser desorption ionization mass spectrometry, nuclear magnetic resonance and 
high performance liquid chromatography. A description of the synthesis and characterization is 
described elsewhere (manuscript in preparation). 
 
Figure 1.  Representative fullerene derivative. 
PMA-induced mouse ear oedema model of inflammation 
Phorbol 12-myristate 13-acetate (Sigma) is a lipophilic, long-acting stimulant of protein kinase C 
(PKC) and elicits a well-characterized delayed-type hypersensitivity reaction (13,14). To induce 
an inflammatory response we used a mouse model of PMA-induced inflammation (15–18). For 
control mice, phosphate-buffered saline (PBS, 20 μl/ear) was injected subcutaneously into the 
left ear approximately 5 min prior to injection with PMA (20 μl of 0.01% w/v per ear in 
acetone). For treated mice, fullerenes in PBS (2 μg/20 μl; 667 μM) were injected subcutaneously 
into the left ear approximately 5 min prior to injection with PMA. The right ear of each mouse 
was not challenged and served as a control to measure differences in the weights of biopsies. 
After 5.5 h, the extent of inflammation was photo-documented and the swelling quantified by 
weighing two separate, 3-mm biopsies obtained at different parts of the left ear (fullerene 
treated ± PMA or non-treated ± PMA) and right ear (non-treated) and calculating the differences 
in weights. Thus, the more the mouse ear weighed the greater the inflammation and oedema. 
Results 
We tested fullerene derivatives for their ability to prevent the acute irritation in a mouse model of 
irritant dermatitis. As seen in Fig. 2a and b, the vehicle-treated ears that received only PBS 
before PMA exhibited considerable redness and swelling as indicated by the arrows. However, 
when fullerenes were injected into the ear prior to PMA challenge there was a noticeable 
inhibition of this response (Fig. 2c and d). Quantification of the ear swelling is shown 
in Fig. 2e as the average change in weight in the left ear of treated and non-treated mice 
compared with the right ear of each. In the PBS ± PMA mice the average increase in ear weight 
was 0.015 g (± SD: 0.01) while the fullerene ± PMA mice had an average increase of 0.002 g 
(±SD: 0.004) indicating that the inflammatory cascade leading to oedema was inhibited when 
fullerenes were used prior to PMA challenge. 
 
Figure 2.  Fullerenes inhibit phorbol 12-myristate 13-acetate (PMA)-induced inflammation. The 
left ears of control mice treated with phosphate-buffered saline (PBS) ± PMA (a,b) or mice 
treated with fullerene ± PMA (c,d) were photo-documented approximately 5.5 h after PMA 
challenge. In the embedded graph (e) mouse biopsies (two per ear) obtained from the left ear of 
fullerene treated ( ) and non-treated (▪) mice (±PMA) were weighed and the average compared 
with the weights of biopsies (two per ear) of non-treated right ears (no PBS, fullerene, or PMA). 
The difference in the average weights (±SD) in grams is shown (n = 4/group). *Indicates 
statistical significance (P = 0.025 using t-test). 
Discussion 
Inflammation occurs naturally within the body and serves a useful purpose in the defense against 
microbes and damaged tissues. Though inflammation is protective in some situations if left 
unchecked or during disease processes this inflammation can lead to serious complications. The 
inflammatory response in general occurs in three distinct phases. Initially, increased vascular 
permeability results in oedema followed by the second phase of leucocytes infiltration. Lastly, 
granuloma formation and tissue repair occur. In this study we demonstrated that fullerenes 
blocked the acute inflammatory mechanisms that led to oedema and leucocyte infiltration. 
It is not clear how the fullerene derivatives inhibited this response. However, we and others have 
demonstrated certain mechanisms of fullerenes which may be relevant here. First, the release of 
histamine and prestored tumor necrosis factor-α from cutaneous mast cells was one well-
characterized component of inflammation (19). We demonstrated that preincubation of mast cells 
with fullerenes significantly inhibited the release of inflammatory mediators in vitro and in 
vivo (8). Second, oxidative stress through the generation of ROS plays a key role in 
inflammatory responses. It has been well documented that PMA-induced PKC activation leads to 
elevated ROS levels in disease-related inflammation (20–22). Given that fullerenes have 
previously been shown to be very potent ROS-inhibiting antioxidants (23) the fullerene 
derivatives described here may inhibit inflammation through blunting ROS and subsequent ROS-
dependent pathways. We are currently focusing on these two theories to determine how 
fullerenes inhibit PMA-induced inflammation in vivo. 
In conclusion, we showed that PMA-induced activation of the inflammatory cascade(s) leading 
to cutaneous inflammation was blocked by certain fullerene derivatives. Such a therapeutic 
intervention that targets these inflammation precursors and blocking their effects may open new 
avenues for controlling inflammation and block diseases associated with unchecked 
inflammation. 
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